4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 12.8% – Here’s Why

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares were up 12.8% on Wednesday . The company traded as high as $9.75 and last traded at $9.78. Approximately 233,290 shares changed hands during trading, a decline of 69% from the average daily volume of 758,013 shares. The stock had previously closed at $8.67.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on FDMT shares. Jefferies Financial Group reiterated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. The Goldman Sachs Group set a $33.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Finally, Chardan Capital reissued a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $29.88.

4D Molecular Therapeutics Trading Up 13.0%

The firm has a market cap of $512.40 million, a PE ratio of -3.81 and a beta of 2.75. The business’s 50-day simple moving average is $9.46 and its 200 day simple moving average is $9.15.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $2.59 million. Analysts expect that 4D Molecular Therapeutics, Inc. will post -3.8 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Sei Investments Co. grew its position in 4D Molecular Therapeutics by 8.9% during the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock worth $120,000 after purchasing an additional 1,050 shares during the last quarter. Martingale Asset Management L P lifted its stake in 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after acquiring an additional 1,303 shares during the period. Dimensional Fund Advisors LP lifted its stake in 4D Molecular Therapeutics by 3.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock valued at $504,000 after acquiring an additional 2,069 shares during the period. Russell Investments Group Ltd. lifted its stake in 4D Molecular Therapeutics by 11.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after acquiring an additional 2,284 shares during the period. Finally, Prelude Capital Management LLC lifted its stake in 4D Molecular Therapeutics by 11.1% during the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock valued at $200,000 after acquiring an additional 2,300 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.